Prakash Deedwania

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11879782/publications.pdf

Version: 2024-02-01

74 papers 9,526 citations

94433 37 h-index 79698 73 g-index

76 all docs

76 docs citations

76 times ranked 10879 citing authors

#	Article	IF	CITATIONS
1	Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure. JAMA - Journal of the American Medical Association, 2000, 283, 1295.	7.4	1,193
2	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	27.0	588
3	Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study. Diabetes Care, 2006, 29, 1220-1226.	8.6	493
4	Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 941-950.	11.4	452
5	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1463-1476.	27.0	430
6	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	1.6	405
7	Hyperglycemia and Acute Coronary Syndrome. Circulation, 2008, 117, 1610-1619.	1.6	397
8	\hat{l}^2 -Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	7.4	377
9	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Journal of the American College of Cardiology, 2009, 53, 298-304.	2.8	373
10	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet, The, 2006, 368, 919-928.	13.7	369
11	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	8.6	346
12	Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Circulation, 2009, 119, 351-357.	1.6	308
13	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence. Circulation, 2015, 132, 691-718.	1.6	303
14	Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease. Journal of the American College of Cardiology, 2008, 51, 1448-1454.	2.8	291
15	Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1131-1139.	4.5	246
16	Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Circulation, 2007, 115, 700-707.	1.6	213
17	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology, 2003, 42, 914-922.	2.8	198
18	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIROOO00000001040.	1.6	193

#	Article	IF	Citations
19	A comparative analysis of the results from 4 trials of \hat{I}^2 -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. Journal of Cardiac Failure, 2003, 9, 354-363.	1.7	164
20	Regional variations in cardiovascular risk factors in India: India heart watch. World Journal of Cardiology, 2012, 4, 112.	1.5	164
21	Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease. American Journal of Medicine, 2015, 128, 219-228.	1.5	161
22	Determinants of Residual Risk in Secondary Prevention Patients Treated With High-Versus Low-Dose Statin Therapy. Circulation, 2012, 125, 1979-1987.	1.6	149
23	Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial. American Heart Journal, 2001, 142, 502-511.	2.7	115
24	Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart Journal, 2019, 71, 309-313.	0.5	110
25	What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?. Journal of the American College of Cardiology, 2005, 45, 252-259.	2.8	96
26	Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 288.	6.1	93
27	Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure. American Journal of Cardiology, 2011, 107, 1208-1214.	1.6	92
28	Tolerability of \hat{l}^2 -Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation, 2002, 105, 1182-1188.	1.6	87
29	Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensityâ€matched study. European Journal of Heart Failure, 2011, 13, 200-206.	7.1	87
30	Sotalol. Drugs, 1987, 34, 311-349.	10.9	86
31	Ambulatory ECGâ€Based Tâ€Wave Alternans Predicts Sudden Cardiac Death in Highâ€Risk Postâ€MI Patients with Left Ventricular Dysfunction in the EPHESUS Study. Journal of Cardiovascular Electrophysiology, 2008, 19, 1037-1042.	1.7	83
32	Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating βâ€Blockers. Journal of Clinical Hypertension, 2011, 13, 52-59.	2.0	66
33	Frequent Atrial Premature Complexes and Their Association With Risk of Atrial Fibrillation. American Journal of Cardiology, 2015, 116, 1852-1857.	1.6	56
34	Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Current Hypertension Reports, 2016, 18, 76.	3.5	51
35	Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy. JAMA Cardiology, 2021, 6, 139.	6.1	50
36	Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial). American Journal of Cardiology, 2010, 106, 221-227.	1.6	44

#	Article	IF	Citations
37	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. Cardiology Clinics, 2011, 29, 137-156.	2.2	40
38	Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: A cross sectional study. Indian Heart Journal, 2014, 66, 280-288.	0.5	40
39	Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. Cardiology Clinics, 2011, 29, 87-103.	2.2	37
40	Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. American Journal of Medicine, 2015, 128, 715-721.	1.5	36
41	Calcium Channel Blockers and Outcomes in Older Patients With Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 945-952.	3.9	32
42	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. American Journal of Medicine, 2015, 128, 426.e1-426.e9.	1.5	31
43	Usefulness of Abnormal Heart Rate Turbulence to Predict Cardiovascular Mortality in High-Risk Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction (from the EPHESUS) Tj ETQq1 1 0.78	34311 4 rgB	T /Ø8erlock 1
44	Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized) Tj ETQq0 0 0 rgB1	「/Qverlock	2 10 Tf 50 462
45	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation: Cardiovascular Genetics, 2012, 5, 51-57.	5.1	21
46	Primary and Secondary Prevention Strategy for Cardiovascular Disease in Diabetes Mellitus. Cardiology Clinics, 2011, 29, 47-70.	2.2	19
47	Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials. American Journal of Cardiology, 2009, 104, 3E-9E.	1.6	18
48	Diabetes and vascular disease. Expert Review of Cardiovascular Therapy, 2008, 6, 127-138.	1.5	17
49	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program. American Heart Journal, 2017, 187, 78-87.	2.7	17
50	Similar clinical benefits from belowâ€ŧarget and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 2018, 20, 359-369.	7.1	17
51	Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. International Journal of Cardiology, 2017, 227, 462-466.	1.7	16
52	An Overview of Glycemic Control in the Coronary Care Unit with Recommendations for Clinical Management. Journal of Diabetes Science and Technology, 2009, 3, 1342-1351.	2.2	15
53	Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial. Journal of the American Society of Hypertension, 2009, 3, 210-220.	2.3	15
54	Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension. American Journal of Medicine, 2021, 134, e252-e263.	1.5	14

#	Article	IF	CITATIONS
55	How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Journal of Interventional Cardiac Electrophysiology, 2003, 7, 264-275.	1.0	13
56	An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation. Core Evidence, 2012, 7, 49.	4.7	12
57	A Propensity-Matched Study of the Association of Diabetes Mellitus With Incident Heart Failure and Mortality Among Community-Dwelling Older Adults. American Journal of Cardiology, 2011, 108, 1747-1753.	1.6	11
58	Characteristics and Outcomes of Patients With Advanced Chronic Systolic Heart Failure Receiving Care at the Veterans Affairs Versus Other Hospitals. Circulation: Heart Failure, 2015, 8, 17-24.	3.9	11
59	The safety and tolerability of beta blockers in heart failure with reduced ejection fraction: is the current underutilization of this evidence-based therapy justified?. Expert Opinion on Drug Safety, 2015, 14, 1855-1863.	2.4	11
60	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3Âtrials. Journal of Clinical Lipidology, 2019, 13, 586-593.e5.	1,5	11
61	The endocannabinoid system and cardiometabolic risk: Effects of CB1 receptor blockade on lipid metabolism. International Journal of Cardiology, 2009, 131, 305-312.	1.7	8
62	Evolving Treatment Options for Prevention of Cardiovascular Events in Highâ€Risk Hypertensive Patients. Journal of Clinical Hypertension, 2007, 9, 883-888.	2.0	7
63	Management of coronary artery disease in patients with type 2 diabetes mellitus. Current Cardiology Reports, 2007, 9, 264-271.	2.9	7
64	Impact of the 2017 ACC/AHA guidelines on the prevalence of hypertension among Indian adults: Results from a cross-sectional survey. International Journal of Cardiology: Hypertension, 2020, 7, 100055.	2,2	7
65	Reducing morbidity and mortality in high risk patients with statins. Vascular Health and Risk Management, 2009, 5, 495.	2.3	6
66	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.	1.6	5
67	Updated risk factors should be used to predict development of diabetes. Journal of Diabetes and Its Complications, 2017, 31, 859-863.	2.3	5
68	Anticoagulation in Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 786-788.	2.8	4
69	Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation. International Journal of Angiology, 2015, 24, 105-112.	0.6	3
70	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. Core Evidence, 2015, 10, 63.	4.7	2
71	Is Increased Use of Mechanical Circulatory Support Devices Justified?. JAMA Internal Medicine, 2015, 175, 1982.	5.1	2
72	Racial differences in mortality in patients with advanced systolic heart failure: Potential role of right ventricular ejection fraction. International Journal of Cardiology, 2014, 177, 255-260.	1.7	1

#	Article	IF	CITATIONS
73	Mechanical Circulatory Support and Rationale for Future Researchâ€"Reply. JAMA Internal Medicine, 2016, 176, 715.	5.1	0
74	An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs. Reviews in Cardiovascular Medicine, 2012, 13, e89-104.	1.4	0